Invitrocue Ltd (ASX:IVQ) chief executive officer Steven Fang speaks to Proactive Investors about the oncology-focused company’s development of cancer treatments by testing specific drugs on laboratory-controlled micro-tumours. “We’ve been able to take some of these really innovative, disruptive technologies and apply it to the space of being able to create these micro-tumours,” says Fang. He continues, “That allows us to test the response of these cancer cells against those specific drugs. “But it’s always done individualised – this whole area of personalised oncology is now coming to market.”
From The Invitrocue Website…
Many cancer treatments today are “one-size-fits-all”. Developed based on studies using large patient numbers from the general population, these treatments don’t take into account the differences between individuals. As a result, patients like you may receive what is considered “standard” treatment. In many cases, it works. However, in the cases where it doesn’t, you will then be given another treatment in the quest to find one that does. This trial-and-error approach means a patient like you may have to go through many treatments before finding the best one – a process that is extremely taxing on both the patient’s health and body, results in loss of critical treatment time, and causes additional financial burdens.
Our scientists at Invitrocue have developed the propriety Onco-PDO® (Patient-Derived Organoid) test, which goes the next step to personalize your cancer treatment. With these results, physicians can prescribe the most appropriate treatment regime that suits your particular type of cancer. Choosing the most effective drugs quickly and accurately will save critical treatment time and boost your chances for the desired positive outcome. With this unique and tailored treatment of your cancer, the myth of the “one-size-fits-all” treatment is no more.